Hualan Biological Engineering Inc operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hualan Biological Engineering Inc with three other
companies in this sector in China:
Tonghua Dongbao Medicines Company Limited
sales of 2.54 billion Chinese Renmimbi [US$371.17 million]
of which 89%
Jinyu Bio-Technology Co Ltd
(1.90 billion Chinese Renmimbi [US$277.64 million]
of which 98%
was Bio-Pharmaecutical), and
China Biologic Products Holdings Inc
(2.49 billion Chinese Renmimbi [US$364.34 million]
of which 100%
was Human Blood Product).
Hualan Biological Engineering Inc reported sales of 2.37 billion Chinese Renmimbi (US$345.87 million)
December of 2017.
increase of 22.4%
versus 2016, when the company's sales were 1.93 billion Chinese Renmimbi.
Sales at Hualan Biological Engineering Inc have increased during each of the previous five years
(and since 2012, sales have increased a total of 144%).
Sales of Vaccine Products saw an increase
that was more than double the company's growth rate: sales were up
157.9% in 2017, from
108.96 million Chinese Renmimbi to 280.98 million Chinese Renmimbi.
Not all segments of Hualan Biological Engineering Inc experienced an increase in sales in 2017:
sales of Other Operations fell 17.9% to 9.00 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).